WHITBY PHARMACEUTICAL ACQUIRES 11 GLAXO PRODUCTS
Executive Summary
WHITBY PHARMACEUTICAL ACQUIRES 11 GLAXO PRODUCTS with aggregate annual sales of $9.5 mil. Whitby announced the purchase Jan. 19. The purchase price was not disclosed. Whitby Pharmaceuticals is the new name (adopted in Sept. 1989) by chemical manufacturer Ethyl Corp's drug marketing business. Ethyl established the drug marketing effort in 1987 as Ethyl Pharmaceutical Inc. Ethyl's finished drug business is made up of Birmingham, Alabama-based Russ Pharmaceuticals (acquired by Ethyl in March, 1989) and the former Nelson Research and Development (acquired in 1987). Nelson has been rechristened Whitby Research. Whitby subsidiary Russ will market the products, which are produced by a contract manufacturer. Russ currently markets a single product line, the Lortab series of hydrocondone-based prescription analgesics. The products involved in the deal are Trinsicon hematinic concentrate, Trinsicon M hematinic modified (without folic acid), vitamin formulations Vicon-C, Vicon Forte, Vicon Plus, and Vi-Zac, the hemorrhoid cream Corticaine (hydrocortisone acetate), asthma treatment Amesec, Ethatab, used in vascular disorders, laxative Athrocholin and antihistamines Histabid and Histabid Duracaps.
|
WHITBY PHARMACEUTICAL ACQUIRES 11 GLAXO PRODUCTS with aggregate
annual sales of $9.5 mil. Whitby announced the purchase Jan. 19.
The purchase price was not disclosed. Whitby Pharmaceuticals is the
new name (adopted in Sept. 1989) by chemical manufacturer Ethyl
Corp's drug marketing business. Ethyl established the drug
marketing effort in 1987 as Ethyl Pharmaceutical Inc. |